Related references
Note: Only part of the references are listed.Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review
Koen Degeling et al.
PHARMACOECONOMICS (2020)
Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?
Christine Semira et al.
INTERNAL MEDICINE JOURNAL (2019)
Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer
Koen Degeling et al.
MEDICAL DECISION MAKING (2019)
The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study
Belinda Lee et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis
Daniel A. Goldstein et al.
ONCOLOGIST (2017)
Recent developments in the treatment of metastatic colorectal cancer
Jonathan M. Loree et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2017)
Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models
Koen Degeling et al.
BMC MEDICAL RESEARCH METHODOLOGY (2017)
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
D. Arnold et al.
ANNALS OF ONCOLOGY (2017)
Review and evaluation of performance measures for survival prediction models in external validation settings
M. Shafiqur Rahman et al.
BMC MEDICAL RESEARCH METHODOLOGY (2017)
Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer
Hui-li Wong et al.
CLINICAL COLORECTAL CANCER (2016)
Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer
James McLean et al.
CLINICAL COLORECTAL CANCER (2016)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Sebastian Stintzing et al.
LANCET ONCOLOGY (2016)
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial
A. Passardi et al.
ANNALS OF ONCOLOGY (2015)
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H. J. Simkens et al.
LANCET (2015)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini et al.
LANCET ONCOLOGY (2015)
Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study
Chieh-Lin Jerry Teng et al.
PLOS ONE (2015)
Tests of calibration and goodness-of-fit in the survival setting
Olga V. Demler et al.
STATISTICS IN MEDICINE (2015)
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
F. Loupakis et al.
EUROPEAN JOURNAL OF CANCER (2014)
KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis
Marie Westwood et al.
HEALTH TECHNOLOGY ASSESSMENT (2014)
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Sequencing of treatment in metastatic colorectal cancer: Where to fit the target?
Sally Temraz et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]
Stephen Clarke et al.
BMC CANCER (2013)
Developing a national database for metastatic colorectal cancer management: perspectives and challenges
K. Field et al.
INTERNAL MEDICINE JOURNAL (2013)
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
David Cunningham et al.
LANCET ONCOLOGY (2013)
Comparative Effectiveness Research in Oncology Methodology: Observational Data
Dawn L. Hershman et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
Zhong-Zhen Guan et al.
Chinese Journal of Cancer (2012)
On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data
Hajime Uno et al.
STATISTICS IN MEDICINE (2011)
Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
Niall C. Tebbutt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
How should variable selection be performed with multiply imputed data?
Angela M. Wood et al.
STATISTICS IN MEDICINE (2008)
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest
Alfredo Falcone et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Fully conditional specification in multivariate imputation
S. Van Buuren et al.
JOURNAL OF STATISTICAL COMPUTATION AND SIMULATION (2006)
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer:: European Organisation for Research and Treatment of Cancer Gastrointestinal Group study 40986
CH Köhne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Addition of bevacizurnab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial
FF Kabbinavar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
RM Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
T Aparicio et al.
BRITISH JOURNAL OF CANCER (2003)
Tumorigenesis -: RAF/RAS oncogenes and mismatch-repair status
H Rajagopalan et al.
NATURE (2002)
Internal validation of predictive models: Efficiency of some procedures for logistic regression analysis
EW Steyerberg et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2001)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
LB Saltz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard et al.
LANCET (2000)
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
S Giacchetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
